AbSci Corporation (ABSI) 옵션

GAPPED UP AH...BEAST!

Can it go to $60 next week like TEM or HIMS?

ABSI READY FOR 6.00

ABSI TRENDTRADE WEEKLY BREAK OUT

ABSI NEXT AI CANCER PLAY...MONSTER IN THE MAKING

ABSI: Clueless about it, since back then!! (THANKS for heads-up!!)

ABSI nice day $4s

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

Wow, President Trump just opened the flood gates for investments into AI and medical approaches. 7.55 before end of February.

https://www.technologynetworks.com/drug-discovery/articles/how-is-ai-being-used-in-drug-discovery-394789

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30:00 AM ET, 01/10/2025 - GlobeNewswire

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.

“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”

Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.

“At Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. “This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”

This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics

ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease.Absci Corporation (ABSI) announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.Tourmaline Bio (TRML) announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board.

AMD is investing $20 million in AI drug startup Absci , which will use AMD chips and software

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.

ABSI: I'm in --- nice deal with AMD!!

3rd quarter results Nov. 12, fyi ANT

2025 gettin' closer, ANT

Approachin' the end of the 6 month tradin' channel, gets interestin' now, fyi imvho ANT

C
A prescription drug bottle filled with 0s and 1s to represent binary code.Francis Scialabba
CFOs are embracing AI, experimenting with new use cases for it throughout the finance function. But some CFOs are tapping the potential of the technology in other ways. At biotech firm Absci, researchers are using AI to develop drugs to treat cancer. (We’re not saying that to make your Claude-drafted emails look bad, we promise.)

Absci’s CFO and CBO, Zach Jonasson, spoke with CFO Brew about how AI is allowing the company to create and test new antibodies faster—and cheaper—than ever before.

Absci uses E. coli—yes, the same bacteria that can give you some nasty infections—to manufacture antibodies that can be used in a variety of therapies. Using a process called “high throughput screening,” it then tests the antibodies, and it patents therapies containing the most promising ones.

Even before ChatGPT burst onto the scene, Absci saw potential in AI. Through its testing of antibodies, the company generated large amounts of data, which it realized could be used to train an AI. In 2021, it acquired a deep learning company called Denovium, which became “the nucleus” that it built a proprietary AI around, Jonasson said.

ABSI under $5

ABSI three month chart

Been 1 year since thus post and what a nice investment. Up 105% I'll take that all day and year long.

It will only take one success to be multi millions

It only takes one success..
Now we're in the cancer realm
My call 8.59 before end of year

touchin' resistance, anyday now imfho ANT

Canada: only 2 things i keep in mind: golden Maple leafs and a master chartist, a magic combo, ANT

moderate volume last few tradin' days but holdin' onto that nice area on the chart, ANT

testin' resistance for the 5th time, this puppy wants to move imvho ANT

imo now it breaks that first resistance at 4,50 are we'll temporarily be hooverin' back to the 50ma area, imo and fyi ANT

4th time knockin' on them 4,50's, it's not if but when it will pierce thru, ANT

recoverin' above 50ma, co is busy, 2025 should be great, meanwhile, we have 4,50 and 5,00 as nxt resistances, patience, ANT

today was third time it tried to break resistance (4,50), comin' down it bounced of that 50ma line perfectly, patience, it is a nice consolidation process so far, ANT

some consolidation just above that 50ma should give us more strength later, jmfho ANT

2 million+ volume again today, xcellent so far, ANT

needs just a bit more volume to break 4,5 resistance imo, patience is key, ANT

and hit now, ANT

daily avg vol in, want to see if 4,50 gets broken, ANT

first things first, added some under 4 bucks, patience, ANT

curious about the nxt resistance at 4,50, looks good so far, ANT

50ma magnet? Let's see, ANT

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 fyi ANT

daily volume intact for awhile now, fyi ANT

https://www.absci.com/gen-absci-eyes-busy-2025-as-lead-ai-designed-candidate-heads-for-clinic/
fyi ANT

ABSI

5,25~~ ANT

Hello 5's again, ANT

ALGO POP....GOT OUT HERE!!

ABSI..IS NOW A WEEKLY BREAK OUT PLAY

ABSI cruisin', one of my longterm holds, ANT

ABSI new 52 hi

6,50~~ ANT